Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2021-12-21 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
Other securityholders documents - English.pdf
Regulatory Filings
2021-12-21 English
News release - English.pdf
Regulatory Filings
2021-12-21 English
Underwriting or agency agreements (or amendment thereto).pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the extension and repricing of share purchase warrants by NeonMind Biosciences Inc. It discusses amendments to warrant terms, including expiry date extension and exercise price reduction, and references compliance with Canadian Securities Exchange policy. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is an update on financing terms related to warrants, which falls under capital or financing activities. The document length is 4348 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-12-17 English
Consent letter of issuer's legal counsel.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm providing consent to be named in a Prospectus Supplement and confirming the accuracy of legal opinions contained therein. It references a Prospectus Supplement dated December 16, 2021, related to an offering of Units by Tetra Bio-Pharma Inc. The document is short (1850 characters) and does not contain financial data or detailed report content. It is essentially a legal consent letter related to a financing document (Prospectus Supplement). This type of document does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a full prospectus or capital raising announcement itself but a legal consent related to such a document. Therefore, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and legal confirmations that do not fit other categories.
2021-12-17 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is titled as a "Best-Efforts Prospectus Offering of Units Term Sheet" for Tetra Bio-Pharma Inc. It contains detailed information about a securities offering, including offering price, units, warrants, commissions, agents, closing date, and listing conditions. The text references a base shelf prospectus filed with Canadian securities regulatory authorities and discusses the offering terms and conditions. This is a capital raising document describing the terms of a financing transaction rather than a financial report or regulatory filing. It is not an annual or interim report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. The content clearly fits the definition of a Capital/Financing Update, which covers updates on company fundraising and financing activities. The document length (7755 characters) and detailed terms support this classification with high confidence.
2021-12-17 English
Prospectus (non pricing) supplement (other than ATM) – English.pdf
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement related to a securities offering by Tetra Bio-Pharma Inc. It discusses the terms of the offering, including the number of units, pricing, agents' fees, over-allotment options, and risk factors. It is a formal disclosure document used to raise capital through the issuance of securities. This type of document fits the definition of a Capital/Financing Update, as it provides updates on company fundraising and capital structure changes. It is not an annual or interim report, earnings release, or regulatory filing of another type. The length and detail confirm it is not merely an announcement but the actual offering document.
2021-12-17 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.